Immune escape: Tumor induced immune suppression and immune escape: Mechanisms and possible solutions

Analyzing T Cell Responses: How to Analyze Cellular Immune Responses against Tumor Associated Antigens

Volumn , Issue , 2005, Pages 43-81

  Whiteside, Theresa L ^a   Campoli, Michael ^b   Ferrone, Soldano ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

HLA expression; immune escape; TCR pMHC interactions; Tumor antigens

Indexed keywords

EID: 35948986516     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/1-4020-3623-X_3     Document Type: Chapter

References (180)

1. Fojo T., Bates S. Strategies for reversing drug resistance. Oncogene 2003; 22:7512-7523.
2. Pommier Y., Sordet O., Antony S., Hayward R.L., Kohn K.W. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004; 23:2934-2949.
3. Renkvist N., Castelli C., Robbins P.F., Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001; 50:51-59.
4. Stevanovic S. Identification of tumour-associated T-cell epitopes for vaccine development. Nat Rev Cancer 2002; 2:514-520.
5. Mocellin S., Mandruzzato S., Bronte V., Lise M., Nitti D. Part I: Vaccines for solid tumours. Lancet Oncol 2004; 5:681-689.
6. Milstein C., Waldmann H. Optimism after much pessimism: what next? Curr Opin Immunol 1999; 11:589-591.
7. Bremers A.J., Parmiani G. Immunology and immunotherapy of human cancer: present concepts and clinical developments. Crit Rev Oncol Hematol 2000; 34:1-25.
8. Naftzger C., Takechi Y., Kohda H., Hara I., Vivjayasaradhi S., Houghton A.N. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci USA 1996; 93:14809-14814.
9. Egen J.G., Kuhns M.S., Allison J.P. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002; 3:611-618.
10. Jakobisiak M., Lasek W., Golab J. Natural mechanisms protecting against cancer. Immunol Lett 2003; 90:103-122.
11. Foster A.E., Forrester K., Li Y.C., Gottlieb D.J. Ex-vivo uses and applications of cytokines for adoptive immunotherapy in cancer. Current Pharmaceutical Design 2004; 10:1207-1220.
12. Liu M., Acres B., Balloul J.M., Bizouarne N., Paul S., Slos P., Squiban P. Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA 2004; 1012:14567-14571.
13. Trikha M., Yan L., Nakada M.T. Monoclonal antibodies as therapeutics in oncology. Curr Opin Biotechnol 2002; 13:609-614.
14. Parmiani G., Castelli C., Dalerba P., Mortarini R., Rivoltini L., Marincola F.M., Anichini A. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 2002; 94:805-818.
15. Durrant L.G., Spendlove I. Cancer vaccines entering Phase III clinical trials. Expert Opin Emerg Drugs 2003; 8:489-500.
16. Berzofsky J.A., Ahlers J.D., Janik J., Morris J., Oh S., Terabe M., Belyakov I.M. Progress on new vaccine strategies against chronic viral infections. J Clin Invest 2004; 114:450-462.
17. Takahashi M. Effectiveness of live varicella vaccine. Expert Opin Biol Ther 2004; 4:199-216.
18. Tjalma W.A., Arbyn M., Paavonen J., van Waes T.R., Bogers J.J. Prophylactic human papillomavirus vaccines: the beginning of the end of cervical cancer. Int J Gynecol Cancer 2004; 14:751-761.
19. Sogn J.A. Tumor immunology: The glass is half full. Immunity 1998; 9:757-763.
20. Marincola F.M., Jaffee E.M., Hicklin D.J., Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74:181-273.
21. Ferrone S. (guest ed.). Tumour immune escape. Semin Cancer Biol 2002; 12:1-86, 403-405.
22. Khong H.T., Restifo N.P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002; 3:999-1005.
23. Whiteside T.L. Apoptosis of immune cells in the tumor microenvironment and peripheral circulation of patients with cancer: implications for immunotherapy. Vaccine 2002; 20 Suppl 4:A46-51.
24. Onyango P. Genomics and cancer. Curr Opin Oncol 2002; 14:79-85.
25. Henderson R.A., Finn O.J. Human tumor antigens are ready to fly. Adv Immunol 1996; 62:217-256.
26. 264-272 peptide in the circulations of patients with head and neck cancer. Cancer Res 2002; 62: 3521-3529.
27. Valmori D., Dutoit V., Lienard D., Lejeune F., et al. Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan A-specific CD8+ T cells in melanoma patients. J Immunol 2000; 165: 533-538.
28. Whiteside T.L., Herberman R.B. Role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol 1995; 7:704-710.
29. Yewdell J. (guest ed.). Generating peptide ligands for MHC class I molecules. Mol Immunol 2002; 39:125-261.
30. Heath W.R., Carbone F.R. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 2001; 19:47-64.
31. Li Z., Menoret A., Srivastava P. Roles of heat-shock proteins in antigen presentation and cross-presentation. Curr Opin Immunol 2002; 14:45-51.
32. Thery C., Amigorena S. The cell biology of antigen presentation in dendritic cells. Curr Opin Immunol 2001; 13:45-51.
33. Cooper M.A., Fehniger T.A., Fuchs A., Colonna M., Caligiuri M.A. NK cell and DC interactions. Trends Immunol 2004; 25:47-52.
34. Foti M., Granucci F., Ricciardi-Castagnoli P. A central role for tissue-resident dendritic cells in innate responses. Trends Immunol 2004; 25:650-654.
35. Ikeda H., Chamoto K., Tsuji T., Suzuki Y., Wakita D., Takeshima T., Nishimura T. The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci 2004; 95:697-703.
36. Raulet D.H. Interplay of natural killer cells and their receptors with the adaptive immune response. Nat Immunol 2004; 5:996-1002.
37. Jego G., Pascual V., Palucka A.K., Banchereau J. Dendritic cells control B cell growth and differentiation. Curr Dir Autoimmun 2005; 8:124-139.
38. Liu.Y.J. Dendritic cell subsets and lineages and their functions in innate and adaptive immunity. Cell 2001; 106: 259-262.
39. Curiel T.J., Wei S., Dong H., Alvarez X., et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 2003; 9:562-567.
40. Creusot R.J., Mitchison N.A. How DCs control cross-regulation between lymphocytes. Trends Immunol 2004; 25:126-131.
41. Heath W.R., Belz G.T., Behrens G.M., Smith C.M., Forehan SP., Parish I.A., Davey G.M., Wilson N.S., Carbone F.R., Villadangos J.A. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 2004; 199:9-26.
42. Mazzoni A., Segal D.M. Controlling the Toll road to dendritic cell polarization. J Leukoc Biol 2004; 75:721-730.
43. Colombo M.P., Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13:155-268.
44. Barry M., Bleackley R.C. Cytotoxic T lymphocytes: all roads lead to death. Nat Rev Immunol 2002; 2:401-409.
45. Coffman R.L., Mocci S., Ogarra A. The stability and reversibility of Th1 and Th2 populations. Curr Top Microbiol Immunol 1999; 238:1-12.
46. Tatsumi, T., Kierstead L.S., Ranieri E., Gesualdo L., Schena F.P., Finke J.H., Bukowski R.M., Mueller-Berghaus J., Kirkwood J.M., Kwok W.W., Storkus W.J. Disease-associated bias in Th1/Th2 CD4+ T cell responses against MAGE-6 in HLA-DRp1*0401+ patients with melanoma or renal cell carcinoma. J Exp Med 2002; 196: 619-628.
47. Pulendran B. Modulating TH1/TH2 responses with microbes, dendritic cells, and pathogen recognition receptors. Immunol Res 2004; 29:187-196.
48. Witz I.P. Presence and functions of immune components in the tumor microenvironment. Adv Exp Med Biol 2001; 495:317-324.
49. Lin E.Y., Pollard J.W. Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer 2004; 90:2053-2058.
50. Whiteside T.L. Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother 1999; 48:346-52.
51. Whiteside T.L. Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol Immunother 2004; 53:865-88.
52. Shurin M.R., Lu L., Kalinski P., Stewart-Akers A.M., Lotze M.T. Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunopathol 1999; 21:339-359.
53. Yamaguchi Y., Ohshita A., Kawabuchi Y., Ohta K., Shimizu K., Minami K., Hihara J., Miyahara E., Toge T. Adoptive immunotherapy of cancer using activated autologous lymphocytes-current status and new strategies. Hum Cell 2003; 16:183-189.
54. Mizoguchi H., O'Shea J.J., Longo D.L., Loeffler CM., McVicar D.W., Ochoa A. Alterations in signal transduction molecules in T lymphocytes from tumor bearing mice. Science 1992; 258:1795-1798.
55. c in T-cell infiltrating human renal cell carcinoma. Cancer Res 1993; 53:5613-5616.
56. Li X., Liu J., Park J.K., Hamilton T.A., Rayman P., Klein E., Edinger M., Tubbs R.R., Bukowski R., Finke J. T cells from renal cell carcinoma patients exhibit an abnormal pattern of NFKB specific DNA binding activity. Cancer Res 1994; 54:5424-5429.
57. Bukowski R.M., Rayman P., Uzzo R., Bloom T., Sandstrom K., Peereboom D., Olencki T., Budd G.T., McLain D., Elson P., Novick A., Finke J.H. Signal transduction abnormalities in T lymphocytes from patients with advanced renal cell carcinoma: clinical relevance and effects of cytokine therapy. Clin Cancer Res 1998; 4:2337-2347.
58. Uzzo R.G., Clark P.E., Rayman P., Bloom T., Rybicki L., Novick A., Bukowski R., Finke J. Evidence that tumor inhibits NFKB activation in T lymphocytes of patients with renal cell carcinoma. J Natl Cancer Inst 1999; 91:718-721.
59. Uzzo R., Rayman P., Kolenko V., Clark P.E., Cathcart M.K., Bloom T., Novick A.C., Bukowski R.M., Hamilton T., Finke J.H. Renal cell carcinoma-derived gangliosides suppress nuclear factor-KB activation in T cells. J Clin Invest 1999; 104:769-776.
60. Reichert T.E., Rabinowich H, Johnson J.T., Whiteside T.L. Human immune cells in the tumor microenvironment: mechanisms responsible for signaling and functional defects. J Immunother 1998; 21:295-306.
61. Kuss I., Saito T., Johnson J.T., Whiteside T.L. Clinical significance of decreased zeta chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin Cancer Res 1999; 5:329-334.
62. Kurt R.A., Urba W.J., Smith J.W., Schoof D.D. Peripheral T lymphocytes from women with breast cancer exhibit abnormal protein expression of several signaling molecules. Int J Cancer 1998; 78:16-20.
63. Nakagomi H., Petersson M., Magnusson I., Juhlin C, Matsuda M., Mellstedt H., Taupin J.L, Vivier E., Anderson P., Kiessling R. Decreased expression of the signal-transducing L, chains in tumor-infiltrating T-cell and NK cells of patients with colorectal carcinoma. Cancer Res 1993; 53:5610-5612.
64. Matsuda M., Petersson M., Lenkei R., Raupin J.L., Magnusson I., Mellstedt H., Anderson P., Kiessling R. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer 1995; 61:765-772.
65. Finke J.H., Zea A.H., Stanley J., Longo D.L., Mizoguchi H., Tubbs R.R., Wiltrout R.H., O'Shea J.J., Kudoh S., Klein E., Bukowski R.M., Ochoa A. Loss of T-cell receptor £ chain and p56 in T-cell infiltrating human renal cell carcinoma. Cancer Res 1993; 53:5613-5616.
66. Li X., Liu J., Park J.K., Hamilton T.A., Rayman P., Klein E., Edinger M., Tubbs R.R., Bukowski R., Finke J. T cells from renal cell carcinoma patients exhibit an abnormal pattern of NFKB specific DNA binding activity. Cancer Res 1994; 54:5424-5429.
67. Lai P., Rabinowich H., Crowley-Nowick PA., Bell M.C., Mantovani G., Whiteside T.L. Alterations in expression and function of signal transduction proteins in tumor associated NK and T lymphocytes from patients with ovarian carcinoma. Clin Cancer Res 1996; 2:161-173.
68. de Gruijl T.D., Bontkes H.J., Peccatori F., Gallee M.P., Helmerhorst T.J., Verheijen R.H., Aarbiou J., Mulder W.M., Walboomers J.M., Meijer C.J., van de Vange N, Scheper R.J. Expression of CD3-zeta on T-cells in primary cervical carcinoma and in metastasis-positive and-negative pelvic lymph nodes. Br J Cancer 1999; 79:1127-1132.
69. Kono K., Ressing M.E., Brandt R.M., Melief C.J., Potkul R.K., Andersson B., Petersson M., Kast W.M., Kiessling R. Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res 1996; 2:1825-1828.
70. Meidenbauer N, Gooding W., Spitler L., Whiteside T.L. Recovery of £ chain expression and changes in spontaneous IL-10 production after PSA-based vaccines in patients with prostate cancer. Br J Cancer 2002; 86:168-178.
71. Wang Q., Stanley J., Kudoh S., Myles J., Kolenko V., Yi T., Tubbs R., Bukowski R., Finke J. T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3- associated kinases are present. J Immunol 1995; 155:1382-1392.
72. Frydecka I., Kaczmarek P., Bocko D., Kosmaczewska A., Morilla R., Catovsky D. Expression of signal-transducing zeta chain in peripheral blood T cells and natural killer cells in patients with Hodgkin's disease in different phases of the disease. Leuk Lymphoma 1999; 35:545-554.
73. Zea A.H., Cutri B.D., Longo D.L., Alvord W.G, Strobl S.L., Mizoguchi H., Creekmore S.P., O'Shea J.J., Powers G.C., Urba W.J., Ochoa A.C. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1995; 1:1327-1335.
74. Rabinowich H., Banks M., Reichert T., Logan T.F., Kirkwood J.M., Whiteside T.L. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after IL-2 therapy. Clin Cancer Res 1996; 2:1263-1274.
75. Reichert T.E., Strauss L., Wagner E.M., Gooding W., Whiteside T.L. Signaling abnormalities and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 2002; 8:3137-3145.
76. Bauernhofer T., Kuss I., Henderson B., Baum A.S., Whiteside T.L. Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer. Eur J Immunol 2003;33:119-124.
77. Kolenko V., Wang Q., Riedy M.C., O'Shea J., Ritz J., Cathcart M.K., Rayman P., Tubbs R., Edinger M., Novick A., Bukowski R., Finke J. Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas. J Immunol 1997; 159:3057-3067.
78. Reichert T.E., Day R., Wagner E., Whiteside T.L. Absent or low expression of the ^ chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res 1998; 58:5344-5347.
79. Kuss I., Rabinowich H., Gooding W., Edwards R., Whiteside T.L. Expression of ^ in T cells prior to IL-2 therapy as a predictor of response and survival in patients with ovarian carcinoma. Cancer Biother Radiopharm 2002; 17:631-640.
80. Yang L., Carbone D.P. Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res 2004; 92:13-27.
81. Mantovani A., Allavena P., Sozzani S., Vecchi A., Locati M., Sica A. Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors. Semin Cancer Biol 2004; 14:155-160.
82. Mantovani A., Bottazzi B., Colotta F., Sozzani S., Ruco L. The origin and function of tumor-associated macrophages. Immunol Today 1992; 13:265-270.
83. Whiteside T.L., Rabinowich H. The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol Immunother 1998; 46:175-184.
84. Andreola G, Rivoltini L., Castelli C, Huber V., Perego P., Deho P., Squarcina P., Accornero P., Lozupone F., Lugini L., Stringaro A., Molinari A., Arancia G, Gentile M., Parmiani G., Fais S. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 2002; 195:1303-1316.
85. Abrahams V.M., Straszewski S.L., Kamsteeg M., Hanczaruk B., Schwartz P.E., Rutherford T.J., Mor G Epithelial ovarian cancer cells secrete Fas ligand. Cancer Res 2003; 63:5573-5581.
86. Taylor D.D., Gercel-Taylor C, Lyons K.S., Stanson J., Whiteside T.L. T-cell apoptosis and suppression of T-cell receptor/CD3-^ by Fas Ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer Res 2003; 9:5113-5119.
87. Medema J.P., de Jong J., van Hall T., Melief C.J., Offringa R. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med 1999; 190:1033-1038.
88. McKallip R., Li R., Ladisch S. Tumor gangliosides inhibit the tumor-specific immune response. J Immunol 1999; 163:3718-3726.
89. Singh R.K., Varney M.L. IL-8 expression in malignant melanoma: implications in growth and metastasis. Histol Histopathol 2000; 15:843-849.
90. Rivoltini L., Carrabba M., Huber V., Castelli C, Novellino L., Dalerba P., Mortarini R., Arancia G, Anichini A., Fais S., Parmiani G Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 2002; 188:97-113.
91. Groh V., Wu J., Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419:734-738.
92. Doubrovina E.S., Doubrovin M.M., Vider E., Sisson R.B., O'Reilly R.J., Dupont B. Vyas, Y. M. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol 2003; 171, 6891-6899.
93. Wu J.D., Higgins L.M., Steinle A., Cosman D., Haugk K., Plymate S.R. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 2004; 114, 560-568.
94. Streit M., Detmar M. Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene 2003; 22:3172-3179.
95. Hoffmann T.K., Dworacki G., Meidenbauer N., Gooding W., Johnson J.T., Whiteside T.L. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 2002; 8:2553-2562.
96. Saito, T., Dworacki, G., Gooding, W., Lotze, M.T., Whiteside, T.L. Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma. Clin Cancer Res 2000; 6:1351-1364.
97. Kuss I., Godfrey T.E., Donnenberg A.D., Whiteside T.L. Low levels of T-cell receptor excision circles (TREC) and pancity of naïve T cells in the circulation of patients with cancer suggest a rapid lymphocyte turnover within the memory compartment. AACR Proc 2002; 43:278.
98. Zippelius A., Pittet M.J., Batard P., Rufer N., de Smedt M., Guillaume P., Ellefsen K., Valmore D., Lienard D., Plum J., MacDonald, H.R., Speiser D.E., Cerottini J.C., Romero P. Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med 2002; 195:485-494.
99. Van Parijs L., Ibrahimov A., Abbas A.K. The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance. Immunity 1996; 93:951-955.
100. Maher S., Toomey D., Condron C., Bouchier-Hayes D. Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. Immunol Cell Biol 2002; 80:131-137.
101. Green D.R., Droin N., Pinkoski M. Activation-induced cell death in T cells. Immunol Rev 2003; 193:70-81.
102. Krueger A., Fas S.C., Baumann S., Krammer P.H. The role of CD95 in the regulation of peripheral T-cell apoptosis. Immunol Rev 2003; 193:58-69.
103. Vitolo D., Zerbe T., Kanbour A., Dahl C., Herberman R.B., Whiteside T.L. Expression of mRNA for cytokines in tumor-infiltrating mononuclear cells in ovarian adenocarcinoma and invasive breast cancer. Int J Cancer 1992; 51:573-580.
104. Rabinowich H., Suminami Y., Reichert T.E., Crowley-Nowick P., Bell M., Edwards R., Whiteside T.L. Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. Int J Cancer 1996; 68:276-284.
105. Lopez C.B., Rao T.D., Feiner H., Shapiro R., Marks J.R., Frey A.B. Repression of interleukin-2 mRNA translation in primary human breast carcinoma tumor-infiltrating lymphocytes. Cell Immunol 1998; 190:141-155.
106. Shurin M.R., Esche C., Lokshin A., Lotze M.T. Tumors induce apoptosis of dendritic cells in vitro. J Immunother 1997; 20:403.
107. Shurin M.R., Gabrilovich D.I. Regulation of dendritic cell system by tumor. Cancer Res Therapy and Control 2001; 11:65-78.
108. Aalamian M., Pirtskhalaishvili G., Nunez A., Esche C., Shurin G.V., Huland E., Huland H., Shurin M.R. Human prostate cancer inhibits maturation of monocyte-derived dendritic cells. Prostate 2001; 46:68-75.
109. Katsenelson N.S., Shurin G.V., Bykovskaia S.N., Shogan J., Shurin M.R. Human small cell lung carcinoma and carcinoid tumor regulate dendritic cell maturation and function. Modern Path 2001; 14:40-45.
110. Shurin G.V., Shurin M.R., Lotze M.T., Barksdale E.M. Gangliosides mediate neuroblastoma-induced inhibition of dendritic cell generation. Cancer Res 2001; 61:363-369.
111. Gabrilovich D.I. Mechanisms and functional significance of tumor-induced dendritic cell differentiation in cancer. Nat Med 2004; 4:941-952.
112. Pirtskhalaishvili G, Shurin G.V., Esche C, Salup R.R., Lotze M.T., Shurin M.R. Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins. Br J Cancer 2000; 83:506-513.
113. Esche C, Shurin G.V., Kirkwood J.M., Wang G.Q., Rabinowich H., Pirtskhalaishvili G, Shurin M.R. TNF-a-promoted expression of Bcl-2 and inhibition of mitochondrial cytochrome c release mediated resistance of mature dendritic cells to melanoma-induced apoptosis. Clin Cancer Res 2001; 7:974s-979s.
114. Pirtskhalaishvili G, Gambotto A., Esche C, Yurkovetsky Z.R., Lotze M.T., Shurin M.R. IL-12 and Bcl-xl gene transfection of murine dendritic cells protects them from prostate cancer-induced apoptosis and improves their antitumor activity. J Urol 2000; 163:105.
115. Terabe M., Matsui S., Park J.M., Mamura M., Noben-Trauth N., Donaldson D.D., Chen W., Wahl S.M., Ledbetter S., Pratt B., Letterio J.J., Paul W.E., Berzofsky J.A. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003; 198:1741-1752.
116. Serafini P., De Santo C, Marigo I., Cingarlini S., Dolcetti L., Gallina G, Zanovello P., Bronte V. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 2004; 53:64-72.
117. Shevach E.M. Regulatory T cells in autoimmunity. Annu Rev Immunol 2000; 18:423-449.
118. Curiel T.J., Coukos G., Zou L., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-949.
119. Gallimore A., Sakaguchi S. Regulation of tumour immunity by CD25+ T cells. Immunology 2002; 107:5-9.
120. Slingluff C.L. Jr., Colella T.A., Thompson L., Graham D.D., Skipper J.C., Caldwell J., Brinckerhoff L., Kittlesen D.J., Deacon D.H., Oei C. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunol Immunother 2000; 48:661-672.
121. Riker A., Cormier J., Panelli M., Kammula U., Wang E., Abati A., Fetsch P., Lee K.H., Steinberg S., Rosenberg S. Immune selection after antigen-specific immunotherapy of melanoma. Surgery 1999; 126:112-120.
122. Saleh F.H., Crotty K.A., Hersey P., Menzies S.W., Rahman W. Autonomous histopathological regression of primary tumours associated with specific immune responses to cancer antigens. J Pathol 2003; 200:383-395.
123. Schmollinger J.C., Vonderheide R.H., Hoar K.M., Maecker B., Schultze J.L., Hodi F.S., Soiffer R.J., Jung K., Kuroda M.J., Letvin N.L. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci USA 2003; 100:3398-3403.
124. Lozupone F., Rivoltini L., Luciani F., Venditti M., Lugini L., Cova A., Squarcina P., Parmiani G., Belardelli F., Fais S. Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice. Eur J Immunol 2003; 33:556-566.
125. Adriance M.C., Gendler S.J. Downregulation of Muc1 in MMTV-c-Neu tumors. Oncogene 2004; 23:697-705.
126. Hoffmann T.K., Nakano K., Elder E.M., Dworacki G., Finkelstein S.D., Appella E., Whiteside T.L, DeLeo A.B. Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants. J Immunol 2000; 165:5938-5944.
127. Francke U., Pellegrino M. A. Assignment of the major histocompatibility complex to a region of the short arm of human chromosome 6. Proc Natl Acad Sci USA 1977; 74:1147-1151.
128. Amiot L., Onno M., Lamy T., Dauriac C., Le Prise P.Y., Fauchet R., Drenou B. Loss of HLA molecules in B lymphomas is associated with an aggressive clinical course. Br J Haematol 1998; 100:655-663.
129. Wetzler M., Baer M.R., Stewart S.J., Donohue K., Ford L., Stewart C.C., Repasky E.A., Ferrone S. HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse. Leukemia 2001; 15:128-133.
130. Drenou B., Le Friec G., Bernard M., Pangault C., Grosset J.M., Lamy T., Fauchet R., Amiot L. Major histocompatibility complex abnormalities in non-Hodgkin lymphomas. Br J Haematol 2002; 119:417-424.
131. Lopez-Nevot M.A., Esteban F., Ferron A., Gutierrez J., Oliva M.R., Romero C., Huelin C., Ruiz-Cabello F., Garrido, F. HLA class I gene expression on human primary tumours and autologous metastases: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas. Br J Cancer 1989; 59:221-226.
132. Torres M.J., Ruiz-Cabello F., Skoudy A., Berrozpe G., Jimenez P., Serrano A., Real F.X., Garrido F. Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. Tissue Antigens 1996; 47:372-381.
133. Scupoli M.T., Sartoris S., Tosi G., Ennas M.G., Nicolis M., Cestari T., Zamboni G., Martignoni G., Lemoine N.R., Scarpa A., Accolla R.S. Expression of MHC class I and class II antigens in pancreatic adenocarcinomas. Tissue Antigens 1996; 48:301-311.
134. Cordon-Cardo C., Fuks Z., Drobnjak M., Moreno C., Eisenbach L., Feldman M. Expression of HLA-A, B, C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res 1991; 51:6372-6380.
135. Cabrera T., Pedrajas G., Cozar J.M., Garrido A., Vicente J., Tallada M., Garrido F. HLA class I expression in bladder carcinomas. Tissue Antigens 2003; 62:324-327.
136. Le Y.S., Kim T.E., Kim B.K., Park Y.G., Kim G.M., Jee S.B., Ryu K.S., Kim I.K., Kim J.W. Alterations of HLA class I and class II antigen expressions in borderline, invasive and metastatic ovarian cancers. Exp Mol Med 2002; 34:18-26.
137. Vitale M., Pelusi G., Taroni B., Gobbi G., Micheloni C., Rezzani R., Donato F., Wang X., Ferrone S. HLA class I antigen downregulation in primary ovary carcinoma lesions. Association with disease. Clin Can Res 2005; 11:67-72.
138. Klein B., Klein T., Konichezky M., Nyska A., Livini E., Levine I., Zamir R., Kooperman O., Lurie H. The expression of HLA class I antigens in germ cell testicular cancer. Am J Clin Pathol 1990; 93:202-207.
139. Natali P.G., Viora M., Nicotra M.R., Giacomini P., Bigotti A., Ferrone S. Antigenic heterogeneity of skin tumors of nonmelanocyte origin: analysis with monoclonal antibodies to tumor-associated antigens and to histocompatibility antigens. J Natl Cancer Inst 1983; 71:439-447.
140. Ruiz-Cabello F., Lopez Nevot M.A., Gutierrez J., Oliva M.R., Romero C., Ferron A., Esteban F., Huelin C., Piris M.A., Rivas C. Phenotypic expression of histocompatibility antigens in human primary tumours and metastases. Clin Exp Metastasis 1989; 7:213-226.
141. Kageshita T., Ono T., Hirai S., Yoshii A., Kimura T., Nakakuma H., Horikawa K., Takatsuki K., Ferrone S. Ganglioside, adhesion molecule, and HLA antigen expression in basal cell carcinoma lesions. Cancer Res 1992; 52:3201-3207.
142. Fukusato T., Gerber M.A., Thung S.N., Ferrone S., Schaffner F. Expression of HLA class I antigens on hepatocytes in liver disease. Am J Pathol 1986; 123:264-270.
143. Kurokohchi K., Carrington M., Mann D.L., Simonis T.B., Alexander-Miller M.A., Feinstone S.M., Akatsuka T., Berzofsky J.A. Expression of HLA class I molecules and the transporter associated with antigen processing in hepatocellular carcinoma. Hepatology 1996; 23:1181-1188.
144. Bi Y., Zhang J., Hong Z., Huang J., Chen J., Wang X., Ferrone S. Association of HLA class I antigen expression in human hepatocellar carcinoma with improved prognosis. Tissue Antigens 2002; 2:105-106.
145. Kageshita T., Hirai S., Ono T., Hicklin D.J., Ferrone S. Downregulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol 1999; 154:745-754.
146. Le Y. S., Kim T.E., Kim B.K., Park Y.G., Kim G.M., Jee S.B., Ryu K.S., Kim I. K., Kim J.W. Alterations of HLA class I and class II antigen expressions in borderline, invasive and metastatic ovarian cancers. Exp Mol Med 2002; 34:18-26.
147. Dammrich J., Muller-Hermelink H.K., Mattner A., Buchwald J., and Ziffer S. Histocompatibility antigen expression in pulmonary carcinomas as indication of differentiation and of special subtypes. Cancer 1990; 65:1942-1954.
148. Yu Z., Restifo N.P. Cancer vaccines: progress reveals new complexities. J Clin Invest 2002; 110:289-294.
149. Bystryn J.C., Zeleniuch-Jacquotte A., Oratz R., Shapiro R.L., Harris M.N., Roses D.F. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res 2001; 7:1882-1887.
150. Belli F., Testori A., Rivoltini L., Maio M., Andreola G., Sertoli M.R., Gallino G., Piris A., Cattelan A., Lazzari I., Carrabba M., Scita G., Santantonio C., Pilla L., Tragni G., Lombardo C., Arienti F., Marchiano A., Queirolo P., Bertolini F., Cova A., Lamaj E., Ascani L., Camerini R., Corsi M., Cascinelli N., Lewis J.J., Srivastava P., Parmiani G. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 2002; 20:4169-4180.
151. Berd D. M-Vax: an autologous, hapten-modified vaccine for human cancer. Expert Opin Biol Ther 2002; 2:335-342.
152. Ward S., Casey D., Labarthe M.C., Whelan M., Dalgleish A., Pandha H., Todryk S. Immunotherapeutic potential of whole tumour cells. Cancer Immunol Immunother 2002; 51:351-357.
153. Rivoltini L., Castelli C., Carrabba M., Mazzaferro V., Pilla L., Huber V., Coppa J., Gallino G., Scheibenbogen C., Squarcina P., Cova A., Camerini R., Lewis J.J., Srivastava P.K., Parmiani G. Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma-and colon carcinoma-specific T cells. J Immunol 2003; 171:3467-3474.
154. Gilboa E. The makings of a tumor rejection antigen. Immunity 1999; 11:263-270.
155. Hoffmann T.K., Meidenbauer N., Muller-Berghaus J., Storkus W.J., Whiteside T.L. Proinflammatory cytokines and CD40 ligand enhanced cross-presentation and cross-priming capability of human dendritic cells internalizing apoptotic cancer cells. J Immunother 2001; 24:162-171.
156. Hillman G.G., Kallinteris N.L., Lu X., Wang Y., Wright J.L., Li Y., Wu S., Forman J.D., Gulfo J.V., Humphreys R.E., Xu M. Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation. Cancer Treat Rev 2004; 30:281-290.
157. Kim J.V., Latouche J.B., Riviere I., Sadelain M. The ABCs of artificial antigen presentation. Nat Biotechnol 2004; 22:403-410.
158. Ferlazzo G., Pack M., Thomas D., et al. Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. PNAS USA 2004; 101; 16606-16611.
159. Thornton M.V., Kudo D., Rayman P., Horton C, Tannenbaum C.S., Molto L., Cathcart M.K., Ng C, Paszkiewicz-Kozik E., Bukowski R., Finke J.H. Degradation of NFKB in T cells by gangliosides expressed on renal cell carcinomas. J Immunol 2004; 172:3480-3490.
160. Labeur M.S., Roters B., Pers B., Mehling A., Luger T.A., Schwarz T., Grabbe S. Generation of tumor immunity by bone marrow derived dendritic cells correlate with dendritic call maturation stage. J Immunol 1999; 62:68-175.
161. Mailliard R.B., Egawa S., Cai Q., Kalinska A., Bykovskaya S.N., Lotze M.T., Kapsenberg M.L, Storkus W.J., Kalinski P. Complementary dendritic cell-activating function of CD8+ and CD4+ cells: helper role of CD8+ T cells in the development of T helper type 1 responses. J Exp Med 2002; 195:473-483.
162. Tatsumi, T., Kierstead L.S., Ranieri E., Gesualdo L., Schena F.P., Finke J.H., Bukowski R.M., Mueller-Berghaus J., Kirkwood J.M., Kwok WW., Storkus W.J. Disease-associated bias in Th1/Th2 CD4+ T cell responses against MAGE-6 in HLA-DRp1*0401+ patients with melanoma or renal cell carcinoma. J Exp Med 2002; 196: 619-628.
163. Mailliard R.B., Son Y.I., Redlinger R., Coates P.T., Giermasz A., Morel PA., Storkus W.J., Kalinski P. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol 2003; 171:2366-2373.
164. Selliah N, Shackelford J., Wang J.F., Traynor F., Yin J., Finkel T.H. T cell signaling and apoptosis in HIV disease. Immunol Res 2003; 27:247-260.
165. O'Connell J., Bennett M.W., O'Sullivan G.C., Collins J.K., Shanahan F. The Fas counterattack: a molecular mechanism of tumor immune privilege. Mol Medicine 1997; 3:294-300.
166. O'Connell J., O'Sullivan G.C., Collins J.K., Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184:1075-1082.
167. Griffith T.S., Brunner S.M., Fletcher S.M., Green D.R., Ferguson TA. Fas ligand-induced apoptosis as mechanism of immune privilege. Science 1995; 270:1189-1192.
168. Green D.R., Ferguson TA. The role of Fas ligand in immune privilege. Nat Rev Mol Cell Biol 2001; 2:917-924.
169. Whiteside T.L. Immune Responses to malignancies. J Allergy Clin Immunol 2003; 111:S677-S686.
170. Whiteside T.L. Immune cells in the tumor microenvironment. In Cancer Immune Therapy: Current and Future Strategies. G. Stohler, P. Walden (eds) Wiley Weinheim pp 95-118, 2002.
171. Balkwill F. Cancer and the chemokine network. Nat. Rev. Cancer 2004; 4:540-550.
172. Balkwill F., Coussens L.M. Cancer and inflammatory link. Nature 2004; 431:405-406.
173. Smyth M.J., Swann J., Kelly J.M., et al. NKG2 D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer. J Exp Med 2004; 200:1325-1335.
174. Piali L., Fichtel A., Terpe H.J., Imhof B.A., Gisler R.H. Endothelial vascular adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J Exp Med 1995; 181:811-816.
175. Uotila P. The role of cyclic AMP and oxygen intermediates in the inhibititon of cellular immunity in cancer. Cancer Immunol Immunother 1996; 43:1-9.
176. Young M.R. Trials and tribulations of immunotherapy as a treatment option for patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2004; 53:375-382.
177. Rodriguez P.C., Quiceno D.G., Zabaleta J., Ortiz B., Zea A.H., Piazuelo M.B., Delgado A., Correa P., Brayer J., Sotomayor E.M., Antonia S., Ochoa J.B., Ochoa A.C. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004; 64:5839-5849.
178. Grohmann U., Fallerino F., Pucetti P. Tolerance, DC and tryptophan: much ado about IDO. Trends Immunol 2003; 24:242-248.
179. Mocellin S., Marincola F., Rossi C.R., Nitti D., Lise M. The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev 2004; 15:61-76.
180. Vicari A.P., Trinchieri G. Interleukin-10 in viral diseases and cancer: exiting the labyrinth. Immunol Rev 2004; 202:223-236.